The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco- Hematologic Disease
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
- Study ID
- NCT06795815
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 99 Years
- Healthy Volunteers
- Not accepted
Interventions
- Go Wish Game — OTHERThe Go Wish Game (GWG) provides a simple tool, composed by 35 cards to identify individual priorities. GWG is welcomed as a first step in clarifying values and personal thoughts linked to the end of life. The GWG discussion will be divided into two meetings. During the first one, the physician instructs the patients and their caregivers on how the GWG works. The patient will be invited to divide the cards into three sets, labeling the content of the cards within each set as: Very important;more or less important and not important. This will be the base for the second meeting. During the second meeting - scheduled within one week - each category of card sets will be discussed with patients and their caregivers. The identification of the most relevant wishes or priorities of each patient will be incorporated into the individual therapeutic plan and the patient will be offered the option to make a formal ACP in the following 4 weeks.
Study Details
This is a mixed-method, device-free and drug-free multicenter interventional study. The study aims at facilitating end-of-life conversations within the doctor-patient relationship through the use of the Go Wish Game (GWG) and supporting patients, their caregivers and healthcare professionals to complete Advance Care Panning documentation. The GWG helps people clarify and identify their priorities, should they be affected by a chronic, disabling and potentially non-healing illness. In fact, the GWG consists of a small deck of cards, and on each card is a concrete action or situation that may be important to a person at the end of life. The "Onco-hema Go wish-ACP" project aims to evaluate the feasibility of a Go Wish Game-based intervention with patients with refractory lymphoma, leukemia or multiple myeloma or advanced solid tumors with prognosis \> 3 months. In terms of secondary objectives, the study aims to. * Evaluate and compare the intervention with hematology and oncology patients in terms of: - Other feasibility indicators; Involvement in CCP pathways; Quality of communication; Meaning of life; Impact on hope; through a series of questionnaires administered to patients and caregivers involved in the intervention * Qualitatively assess the acceptability of the intervention in terms of recruitment and delivery with patients and caregivers through semi-structured interviews and with professionals through Focus Groups (FGs). * To analyze the clinical records of enrolled patients in terms of: values and preferences; awareness of prognosis; end-of-life choices and shared decision-making on treatment decisions.
Key Dates
- First listed
- Jan 28, 2025
- Start date
- Jun 30, 2025
- Status verified
- May 2026
- Primary completion
- Jul 31, 2026
- Completion
- Jul 31, 2026
Study Design
- Enrollment
- 75 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Experimental: Patients affected by refractory lymphomas, or leukemia or myeloma multiple or advanced solid tumors
Primary Outcome Measure
Intervention Feasibility [ Time Frame: 1 Year ]
Central Contacts
- Marta Perin (Dr), PhD+39 3463576133
- Andrea Fusco, MSc+39 3409136595
Find similar trials
Related Studies
- Bone Marrow Grafting for Leukemia and LymphomaEnrolling By Invitation · Stanford University · Stanford, California
- Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative DisordersRecruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With CancerRecruiting · Barbara Ann Karmanos Cancer Institute · Detroit, Michigan
- Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruiting · UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina